Halia Therapeutics – Eliminating Chronic Inflammation by Targeting the NLRP3 Inflammasome

Dr. David Bearss, PhD, President and CEO at Halia Therapeutics, a clinical-stage biopharma company developing novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases discusses the company’s lead compound, HT-6184, which prevents the formation of the NLRP3 inflammasome complex and subsequently inhibits the production and release of pro-inflammatory cytokines to ultimately shut down chronic inflammation. Halia is currently conducting a Phase 1 trial to evaluate the safety, tolerability, and pharmacokinetics of HT-6184 in healthy human participants.